MorphoSys AG (MorphoSys) is a biopharmaceutical company that develops monoclonal antibodies for therapeutic and research applications, with a focus on the treatment of cancer and autoimmune diseases. The company’s clinical programs include Pelabresib, a small molecule BET inhibitor for anti-tumor activity and Tulmimetostat, a dual inhibitor of EZH2 and EZH1 for anti-tumor activity. It provides clinical trials for cancer and inflammatory disorders. Morphosys also conducts research and development activities with pharmaceutical and biotechnology companies. It operates through subsidiaries in the US and Germany. MorphoSys is headquartered in Planegg, Bayern, Germany.
Headquarters
Germany
Address
Semmelweisstr. 7, Planegg, Bayern, 82152
Website
www.morphosys.com
Telephone
49 89 899270
No of Employees
524
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
MOR (ETR)
Revenue (2022)
$257.7M
-14.4%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-25.6%
(2022 vs 2021)
Market Cap*
$2.7B
Net Profit Margin (2022)
XYZ
-46.7%
(2022 vs 2021)
* As of and is in US$
MorphoSys AG premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Pelabresib (Target BET Inhibitor): |
| Myelofibrosis (MANIFEST-2) |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In February, the company entered into an agreement to be acquired by Novartis AG for US$2.9 billion. |
| 2022 | Contracts/Agreements | In December, Constellation Pharmaceuticals entered into a global licensing agreement with Novartis to research, develop and commercialize its pre-clinical inhibitors of a novel cancer target. |
| 2022 | Others | In August, the company received consensus rating of hold from analysts. |
Competitor Comparison
| Key Parameters | MorphoSys AG | Biotest AG | PAION AG | Hameln Pharma GmbH | Viramed Biotech AG |
|---|---|---|---|---|---|
| Headquarters | Germany | Germany | Germany | Germany | Germany |
| City | Planegg | Dreieich | Aachen | Hameln | Planegg |
| State/Province | Bayern | Hessen | Baden-Wurttemberg | Niedersachsen | Bayern |
| No. of Employees | 524 | 2,426 | 64 | 66 | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Jean-Paul Kress, M.D. | Chief Executive Officer | Senior Management | 2019 | 58 |
| Lucinda Crabtree | Chief Financial Officer | Senior Management | 2023 | 44 |
| Barbara Krebs-Pohl, Ph.D. | Chief Business Officer | Senior Management | - | - |
| Thomas Biegi | Senior Vice President; Head - Corporate Affairs | Senior Management | - | - |
| Joe Horvat | General Manager - MorphoSys US | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward